Article ID Journal Published Year Pages File Type
3981322 Clinical Radiology 2016 6 Pages PDF
Abstract

•In 28 patients (45%), CT and SRS were correct and in agreement in the detection of primary tumor/metastases.•In 34 patients (55%) one of the modalities was incorrect and therefore, there was no agreement.•Sensitivity to detect the primary tumor with CT and SRS were 95% versus 73%.•SRS altered the TNM classification in 14 patients (23%) and clinical management in 9 patients (15%).

AimTo determine whether somatostatin receptor scintigraphy (SRS) influences the preoperative staging and clinical management of non-functioning pancreatic neuroendocrine tumours (NF-pNETs).Materials and methodsAll SRS examinations performed between 2002–2013 were selected. Patients with NF-pNET were included if both computed tomography (CT) and SRS was performed during preoperative staging. The diagnostic accuracy of CT and SRS for detecting NF-pNET metastases was analysed. Altered TNM classification and changed clinical management were calculated. Changed management was defined as a change from surgical resection into systemic treatment or vice versa. NF-pNETs were defined as tumours without clinical symptoms of hormonal hypersecretion.ResultsOverall, 62 patients with NF-pNET were included with a mean age of 57 years (SD: 12.4)2. In 28 patients (45%), CT and SRS were correct and in agreement in the detection of primary tumour/metastases. In 34 patients (55%), one of the techniques was incorrect and therefore, there was no agreement. SRS altered the TNM classification in 14 patients (23%) and clinical management in nine patients (15%). In patients without metastases on CT, SRS detected lymph node metastases in one patient. The sensitivity to detect the primary tumour with CT was 95% and with SRS was 73%. In detecting metastases, the sensitivity and specificity were both 85% for CT versus 80% and 90% for SRS.ConclusionOverall, CT and SRS were in agreement in the detection of NF-pNET. In NF-pNET without suspicious metastatic lesions on CT, SRS has limited value. SRS may be indicated to confirm lesions suspicious for neuroendocrine tumours metastases.

Related Topics
Health Sciences Medicine and Dentistry Oncology
Authors
, , , , , ,